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Abstract 
 We examined immune and inflammatory activation during remission in patients with Crohn's disease who 
presented with various clinical profiles (prolonged remission vs. relapsing disease). Thirty-six patients with at 
least 3 years' follow-up starting from a remission period were studied retrospectively. Relapses were defined by a 
retrospective calculation of the Crohn's disease activity index or by the clinical judgement of the physicians in 
charge of the patients. Disease course over the study period was assessed by the mean number of annual relapses. 
Analysis used measurements during remission of the following: erythrocytes sedimentation rate, relative 
lymphocytosis, acid α1-glycoprotein, interleukin-6 (IL-6), and soluble interleukin-2 receptor (sIL-2R) serum 
levels. During the study period 21 patients experienced at least one relapse and 15 did not. Mean serum levels of 
sIL-2R and mean relative lymphocytosis in remission significantly discriminated between relapsing and 
nonrelapsing patients. Only the mean sIL-2R serum level was selected by multivariate analysis, with a cutoff 
value of 82 pM/1 (sensitivity of 76% and specificity of 80%). The only features correlated with mean number of 
annual relapses in the relapsing patients were mean serum levels of sIL-2R (r = 0.58, P = 0.015) and IL-6 in 
remission (r = 0,45, P = 0.039). Multivariate analysis demonstrated statistical significance only for the mean 
serum level of IL-6 (P = 0.014). In Crohn's disease the persistent elevation in sIL-2R serum levels during 
remission corresponds to chronic active disease, while high serum levels of IL-6 in these patients is associated 
with a high frequency of relapse. 
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INTRODUCTION 
Crohn's disease (CD) is a chronic relapsing inflammatory bowel disease of unknown cause. The natural history 
of the disease varies considerably from one patient to another, with some patients experiencing frequent relapses 
while others have prolonged periods of remission. Several immune or inflammatory parameters have been shown 
to be correlated with disease activity [1, 2, 3, 4, 5, 6]. However, a few of these remain elevated in some patients 
despite clinical remission and may be useful in predicting clinical relapse [4, 7, 8, 9]. In particular we have found 
the interleukin-6 (IL-6) serum level, acid α1-glycoprotein, soluble interleukin-2 receptor (sIL-2R) serum level, 
and relative lymphocytosis to be good predictors of relapse [4,7]. The state of immune and inflammatory 
activation during clinical remission of CD remains unclear. It may be different in prolonged remission as 
compared to frequently relapsing disease. In the latter, remission may reflect either complete immune and 
inflammatory inactivation interrupted by frequent reactivation or subclinical persistent disease with transient 
exacerbations giving rise to clinical manifestations. A recent study has shown that the risk of relapse is 
associated with a persistent increase in proinflammatory cytokines production at the mucosal level [10]. 
According to this hypothesis, patients with relapsing disease may have higher mean serum levels of immune and 
inflammatory parameters while in remission than patients with extinguished disease. It is important to determine 
the pathway of this possibly persistent immune and inflammatory activation, with parameters such as sIL-2R 
reflecting lymphocyte activation and IL-6 more macrophage activation. 
The aims of our work were twofold. First, to compare repeated measures of immune and inflammatory 
parameters in remission of CD in patients characterized by either of two different clinical profiles: prolonged 
remission and relapsing disease. Secondly, in patients with relapsing disease to assess the correlation between 
these parameters and the frequency of relapse. 
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PATIENTS AND METHODS 
Patients and study design 
We studied 36 CD patients with at least 3 years' follow-up at the same medical center (University Hospital of 
Liège), and starting with a period of clinical remission defined by a Crohn's disease activity index (CDAI [11]) 
lower than 150. These patients had previously been included in a prospective study on relapse of CD over a 1-
year period [7]. Diagnosis of CD was based on standard criteria. The notes on these patients were analyzed 
retrospectively. Clinical relapses were defined either by a retrospective calculation of the CDAI (CDAI >150 
with an increase greater than 100 compared to the CDAI at inclusion, or a CDAI >200) or by the judgement of 
the clinician in charge of the patients (J.B. or E.L.) found in the notes on the patient; this corresponded to a 
significant change in symptoms requiring a modification in treatment. Disease course was assessed in terms of 
the mean number of annual relapses. 
Patients were treated during remission daily with either 2-4 g 5-aminosalicylic acid (n=29) or 2 mg/kg 
azathioprine (n=17), sometimes associated with low-dose steroids (n=19). In 21 patients the treatment changed 
during follow-up. Patients were divided in two groups: those in group A showed no relapse during follow-up 
(n=15) and those in group B at least one relapse (n=21). As the treatment used, mainly azathioprine, may affect 
inflammatory parameters, we also analyzed the data in subgroups of patients depending on this parameter. 
Patients' characteristics are shown in Table 1. 
 
Table 1 Patients characteristics 
 All patients (n=36) Group A (n=15) Group B (n=21) 
Age (years) 39.8 (21-84) 41.4 (21-84) 38.6 (25-74) 
Women/men 25/11 9/6 16/5 
Duration of follow-up (years) 4.7 (3-9) 4.6 (3-9) 4.7 (3-7) 
Duration of disease (years) 11.6 (5-34) 13.8 (5-34) 10.4 (6-25) 
Familial history (%) 11 13 9.5 
Previous resection surgery (%) 55.5 60 52.4 
Disease location (%)    
Ileal 8 7 10 
Colonic 28 7 43 
Ilecolonic 58 73 47 
Multiple (including upper GI) 6 13 4 
Anal lesions 47 60 33 
Remission treatment (%)    
5-Aminosalicylic acid 80 80 81 
Azathioprine 47 33 57 
Corticoids 53 33 66 
Number of annual relapses per year 0.30 ± 0.36 0 0.50 ± 0.30 
 
Laboratory tests 
The parameters studied were selected on the basis of our previous studies in which more than 30 clinical or 
biological parameters were tested [4, 7]. Erythrocyte sedimentation rate (ESR), relative lymphocytosis, and acid 
α1-glycoprotein serum level were determined using standard procedures. Serum samples were stored at -20°C 
before use in measuring cytokines. The serum level of sIL-2R was measured using a commercial double-
antibody sandwich-linked immunosorbent assay detecting the α-chain (p55) of the receptor (Boehringer-
Mannheim). Serum level of IL-6 was measured using a commercial enzyme-amplified sensitivity immunoassay 
based on an oligoclonal system in which several monoclonal antibodies directed against distinct epitopes of the 
cytokine are used (Medgenix). The analysis used each measurement of these parameters performed in remission 
during the study period, at variable intervals according to the clinical requirement. The mean number of 
measures over the study period were 4.6 ± 3 for ESR (range 2-16), 7.8 ± 4.5 for relative lymphocytosis (range 3-
18), 7.2 ± 4.6 for acid α1-glycoprotein (range 2-18), 7.8 ± 4.4 for sIL-2R (range 3-18), and 4.4 ± 2.7 for IL-6 
(range 2-12). 
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Statistics analysis 
Mean values of biological parameters measured in remission were computed for each patient. A log transform 
was used to normalize the distribution of some variables. Results are expressed as mean ±SD. We first compared 
immune and inflammatory profiles between relapsing (group B) and nonrelapsing disease (group A). 
Student's t test was used to compare the various parameters studied between groups A and B. A stepwise logistic 
regression was then used to select independent parameters discriminating between groups A and B. In group B 
we then evaluated the correlation between immune and inflammatory parameters during remission and the 
disease course as defined by the mean number of annual relapses. A stepwise multiple regression used the mean 
annual number of relapses as dependent variable and inflammatory markers as independent variables. Results 
were considered statistically significant at the level of P < 0.05). Statistical calculations were carried out using 
the SAS package (SAS Institute, Cary, N.C., USA). 
RESULTS 
The results of laboratory tests are shown in Table 2. 
 
Table 2 Biological profiles 
 All patients (n=36) Group A (n=15) Group B (n=21) Normal values 
ESR (mm/h) 14 ± 10 11 ± 8 17 ± 11 0-10 
Relative lymphocytosis (%) 22.5 ± 7.0 25.3 ± 6.3 20.5 ± 6.9 11.0-53.0 
Acid α1-glycoprotein (g/l) 1.09 ± 0.34 0.95 ± 0.20 1.20 ± 0.39 0.4-0.9 
sIL-2R (pM/l) 96 ± 37 77 ± 20 109 ± 41 50-100 
IL-6 (pg/ml) 13.5 ± 12.0 11.1 ± 13.1 15.3 ± 11.0 0-8.5 
 
Comparison of immune and inflammatory profiles between groups A and B  
Univariate analysis showed only mean sIL-2R serum level and mean relative lymphocytosis to discriminate 
between the two groups (P = 0.003 and P = 0.043 respectively). The stepwise logistic procedure selected only 
the mean sIL-2R serum level (P = 0.009) as discriminating between relapsing and nonrelapsing patients. We 
determined the optimal cutoff value of mean sIL-2R serum level for discriminating between the two groups by 
means of a receiver-operating characteristic curve. This cutoff value was 82 pM/l and discriminated between the 
two groups with a sensitivity of 76% and a specificity of 80% (Fig. 1). Regarding only patients treated with 
azathioprin, sIL-2R was still significantly higher in group B than A (124 ± 68 pM/l versus 75 ± 19 pM/l, P = 
0.009) and lymphocytosis was still significantly lower in group B than in group A (17.3 ± 6.3% versus 24.5 ± 
5.6%, P = 0.045).  
 
Fig. 1 Receiver-operating characteristic curve for sIL-2R serum levels in remission of CD discriminating 
between relapsing and nonrelapsing patients 
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Correlation between immune and inflammatory parameters and evolutivity of the disease in patients with 
relapsing disease (group B) 
The only parameters correlated with mean number of annual relapses were mean serum levels during remission 
of ΓL-6 (r = 0.58, P = 0.015) and sIL-2R (r = 0.45, P = 0.039; Table 3, Figs. 2, 3). The stepwise multivariate 
procedure selected only mean IL-6 serum level. This parameter explained 66% of the variance in mean number 
of annual relapse (P = 0.014). 
 
Table 3 Correlations between mean number of annual relapses and mean levels of immune and inflammatory 
parameters during remission in group B 
 n r P 
sIL-2R 21 0.45 0.039 
IL-6 18 0.58 0.015 
Relative lymphocytosis 21 -0.35 NS 
Acid αl-glycoprotein 21 0.33 NS 
ESR 21 0.01 NS 
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DISCUSSION 
We found that patients with relapsing CD are characterized by persistently higher sIL-2R serum levels during 
remission than are patients with prolonged quiescent disease. Furthermore, in patients with relapsing CD the 
frequency of relapse is well correlated with the mean serum level of IL-6 during remission. Several studies have 
shown the persistence of biological and functional abnormalities in some patients with clinically quiescent CD. 
In particular, a persistent elevation in inflammatory markers such as C-reactive protein [9], α2-globulin [8], ESR 
[8], and acid α1-glycoprotein [8] have been shown. We also found a persistent elevation in BL-6 and sIL-2R 
serum levels. These findings may reflect either remaining lesions [12], activation of the mucosal immune system 
[10], or abnormal intestinal permeability [13]. These biological or functional abnormalities have also been 
reported to be associated with an increased risk of relapse assessed over a short to medium period of time 
(usually 1 year) [4,7, 8, 9,10,13,14]. 
The present study considered disease course as defined by the mean number of annual relapse over a longer 
period of time. Our working hypothesis was that patients with no relapse over a period of several years would 
have an extinguished immune and inflammatory activity while patients with frequent relapses would have 
ongoing immune and inflammatory reaction even when in clinical remission. Multivariate analysis revealed the 
only parameter to discriminate between relapsing and nonrelapsing CD was mean sIL-2R serum level measured 
during remission. This most probably reflects an ongoing activation of T lymphocytes characterizing the chronic 
relapsing disease. Indeed the measured sIL-2R corresponds to the α-chain of cellular interleukin-2 receptor (α-
chain + β-chain) released in a soluble form in proportion to its cell surface expression [15]. It is therefore related 
to the activation of cell population that express this receptor, i.e., mainly activated T lymphocytes. 
The origin of this circulating sIL-2R must be discussed. In normal subjects the sIL-2R serum level is correlated 
with sIL-2R production by lamina propria mono-nuclear cells in culture [16]. In CD the sIL-2R serum level is 
increased in active disease [3, 17, 18, 19], is correlated with sIL-2R level in the supernatants of lamina propria 
mononuclear cells in culture [16], and is higher in mesenteric vein than in peripheral veins [17]. In a previous 
study we have shown both the lack of correlation between sIL-2R serum level and cIL-2R positive cells in the 
blood and a negative correlation between sIL-2R serum level and blood lymphocytosis [4]. Together with 
previous data, these findings suggest that sIL-2R serum levels reflect mucosal rather than peripheral blood T 
lymphocyte activation. 
It is noteworthy that in univariate analysis the presence of relative lymphocytopenia discriminated as well 
between relapsing and nonrelapsing disease. Lymphocytopenia may be due in part to mucosal migration of T 
lymphocytes. Lymphocytopenia has previously been described as a predictive marker of relapse after curative 
surgery [20]. None of the other parameters - IL-6, acid α1-glycoprotein, and ESR - discriminated between 
relapsing and nonrelapsing disease. This may be because these parameters are less specific for mucosal immune 
and inflammatory activation in CD, being elevated also in other ordinary circumstances. Overall these results 
suggest that chronic relapsing disease differs from extinguished disease by a persistent activation and probably 
migration of T lymphocyte to the gut mucosa. 
Considering only patients with relapsing disease, the mean IL-6 serum level during remission was the only 
parameter in the multivariate analysis that was correlated with the number of annual relapses. Mean sIL-2R 
serum level, however, was also selected in univariate analysis. This suggests that in frequently relapsing disease 
the ongoing immune activation involves not only sIL-2R but also IL-6 secreting cells and thus probably both 
lymphocytes and other cells such as macrophages or intestinal epithelial cells [21, 22, 23,24,25]. 
Both the mean number of annual relapses and the serum levels of immune and inflammatory parameters may 
have been affected by the treatment during remission, particularly immunosuppressive treatments. Azathioprine, 
which was used in almost one-half of our patients, may have induced a decreased both in lymphocytosis and in 
circulating sIL-2R or IL-6. However, when considering only patients under azathioprine during remission, mean 
serum level of sIL-2R was still higher in relapsing (n=5) than nonrelapsing (n=9) patients, and mean 
lymphocytosis was still lower in relapsing than in nonrelapsing patients. 
CONCLUSION 
These results do not imply that sIL-2R and IL-6 are the main actors in the mucosal immune reactions. Verifying 
such a conclusion would require study of the cytokine profile at the mucosal level [10]. However, at this stage 
we can confirm that a persistent elevation in sIL-2R serum levels during remission is associated with frequently 
relapsing CD, and that in relapsing patients high serum levels of IL-6 during remission reflect a particularly high 
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frequency of relapse. Further studies must clarify whether these serum levels are associated only with persistent 
mucosal or systemic immune activation or also with persistent subclinical abnormalities such as increased 
intestinal permeability or even persistent mucosal macroscopic lesions. 
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